Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases

L. G. Feun, Y. Y. Lee, C. Plager, N. Papadopoulos, N. Savaraj, C. Charnsangavej, R. S. Benjamin, S. Wallace

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Twenty-three patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with intracarotid cisplatin-based chemotherapy. Twenty-two had failed prior cranial radiation therapy (one patient refused radiation therapy) and had progressive brain metastases documented by computerized tomography (CT). Intracarotid cisplatin 40-75 mg/m2 was administered alone (seven patients) with 1,3-bis(2-Chloroethyl)-1-nitrosurea (BCNU) (13 patients) or bleomycin (three patients). Courses were repeated monthly with CT scan. Seven patients (30%) had objective improvement in CT scans and three patients (13%) had stabilization of disease. The median time to tumor progression for responding patients was 20 weeks (range 8-34 weeks) while stable disease ranged from 9-12 weeks. In three patients the extracranial disease progressed while the brain metastases responded. Neurological and retinal toxicity were potential complications of therapy. Intracarotid cisplatin-based chemotherapy may be useful for palliation in selected patients with malignant melanoma and CNS metastases.

Original languageEnglish (US)
Pages (from-to)448-451
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number5
DOIs
StatePublished - Jan 1 1990

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases'. Together they form a unique fingerprint.

  • Cite this